Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for LH and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for LH and 80,000+ other tickers.
See exactly how LH's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LH and 80,000+ other tickers.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused.
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
LH's Q3 earnings may benefit from strong diagnostics demand, specialty testing expansion and acquisitions, with revenues projected to grow 5.7%.
BURLINGTON, N.C., Oct. 21, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valued at $210 million, plus the value of the unit's inventory upon closing.